Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: Norgine
Norgine House
Widewater Place
Moorhall Road
Harefield
Uxbridge
UB9 6NS UK
Tel: +44 (0) 1895 826 600
Norgine is a specialty pharmaceutical company with an extensive and balanced pan-European presence. Above and beyond Europe, its products are sold in a total of 53 countries worldwide. Its areas of expertise are principally in gastroenterology, hepatology and incontinence.
Founded in 1906 by Dr Victor Stein, Norgine is still privately owned and Peter Stein, a grand-nephew of the founder, is now Chairman and CEO. The company’s core focus is on gastroenterology and hepatology. Norgine develops and manufactures innovative pharmaceutical products, which are then marketed through their own subsidiaries and in collaboration with a network of partners around the world.
Norgine’s total revenue in 2009 was €257 million. In 2009 product sales increased to €253 million, the 23rd consecutive year of double-digit growth at constant exchange rates. MOVICOL is Norgine’s number one product and accounts for over 50% of total sales.
Norgine currently has a strong product development pipeline including a number of projects entering advanced clinical studies.
The company has a manufacturing facility in the UK, but no R&D.
Movicol
Moviprep
Klean-Prep
Oramorph
Normacol
Pyralvex
Spasmonal
Fivasa
Nortussine
Xifaxan
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
See our Cookie Privacy Policy Here
